What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Immune system
Mark S. Cragg mostly deals with Cell biology, Monoclonal antibody, Immunology, Antibody and CD20.
He has researched Cell biology in several fields, including Molecular biology and Apoptosis, Programmed cell death, Genetics.
His study explores the link between Monoclonal antibody and topics such as Antigen that cross with problems in Cancer research.
His biological study spans a wide range of topics, including Cell surface receptor, Intracellular and In vivo.
The various areas that Mark S. Cragg examines in his Antibody study include Receptor and Cytotoxicity.
His CD20 research includes themes of Monoclonal, B cell, Rituximab, Chronic lymphocytic leukemia and Immunotherapy.
His most cited work include:
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (4170 citations)
- Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas (593 citations)
- Mechanisms of killing by anti-CD20 monoclonal antibodies. (452 citations)
What are the main themes of his work throughout his whole career to date?
Mark S. Cragg mainly focuses on Immunology, Monoclonal antibody, Cancer research, Antibody and Cell biology.
Rituximab, CD20, B cell, Monoclonal and Antibody-dependent cell-mediated cytotoxicity are among the areas of Immunology where he concentrates his study.
The study incorporates disciplines such as T cell, Epitope, Antigen, In vivo and Immunotherapy in addition to Monoclonal antibody.
Mark S. Cragg studied Cancer research and B-cell receptor that intersect with Signal transduction.
His Antibody research incorporates elements of Receptor, Immune system and Effector.
His work deals with themes such as Autophagy, Cell, Molecular biology and Chromatin, which intersect with Cell biology.
He most often published in these fields:
- Immunology (40.31%)
- Monoclonal antibody (34.11%)
- Cancer research (32.56%)
What were the highlights of his more recent work (between 2018-2021)?
- Antibody (30.23%)
- Cancer research (32.56%)
- Monoclonal antibody (34.11%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Antibody, Cancer research, Monoclonal antibody, Immune system and Immunology.
His research in Antibody intersects with topics in Inflammation, Pharmacology, In vivo and Cell biology.
He interconnects Lymphoma, Rituximab, Cancer immunotherapy, Signal transduction and Chronic lymphocytic leukemia in the investigation of issues within Cancer research.
His research integrates issues of Autophagy, Bcr signaling and Computational biology in his study of Chronic lymphocytic leukemia.
His studies deal with areas such as Epitope, Receptor, Effector and Immunotherapy as well as Monoclonal antibody.
His work carried out in the field of Immunology brings together such families of science as Nod and Disease.
Between 2018 and 2021, his most popular works were:
- Cartilage-binding antibodies induce pain through immune complex-mediated activation of neurons. (28 citations)
- Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens. (27 citations)
- The Cancer Aneuploidy Paradox: In the Light of Evolution (24 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Immune system
Mark S. Cragg mainly focuses on Cell biology, Cancer research, Immunotherapy, Antibody and Monoclonal antibody.
His Cell biology research is multidisciplinary, incorporating perspectives in FCGR2B, T cell, CD8, Fc receptor and Cytotoxic T cell.
The concepts of his Cancer research study are interwoven with issues in Apoptosis, PI3K/AKT/mTOR pathway, Downregulation and upregulation, Lymphoma and Kinase.
His Immunotherapy research is multidisciplinary, incorporating elements of Allergic response, Peanut allergy and Vaccination.
His studies in Antibody integrate themes in fields like Immunohistochemistry, Antagonist and Pharmacology.
His Monoclonal antibody research is multidisciplinary, relying on both Receptor and Peripheral blood mononuclear cell.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
